Drug news
FDA approves Ferriprox for Iron Overload in Thalassemia patients
The FDA has approved Ferriprox from ApoPharma a subsidiary of generic manufacturer Apotex Inc, as a treatment for Iron Overload due to blood transfusions in patients with thalassemia when current chelation therapy is inadequate. This treatment can be vital for thalassemia patients of whom approximately one quarter are not able to manage Iron Overload with currently available treatment. Iron Overload can lead to organ failure and early death. Ferriprox is already approved in the EU and marketed there by Swedish Orphan Biovitrium.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins